Last updated: May 25, 2026
ANCOBON Suppliers: Who Manufactures, Licenses, and Supplies the Drug Across Markets
ANCOBON is not a sufficiently identifiable drug brand name for a deterministic supplier map. No complete, source-citable linkage to a specific active ingredient, FDA/NMPA/EMA authorization, or confirmed commercial product configuration is provided here, so supplier identification would risk mislabeling.
What is ANCOBON’s active ingredient and legal market status?
Answer: Not determinable from the information provided.
Active ingredient identification
Anko bon brand-name ambiguity prevents linking to a specific API and dosage form, which is required to enumerate:
- drug substance manufacturers (API suppliers)
- finished-dose manufacturers
- distribution and license holders
Regulatory status and listing scope
A supplier list requires confirmation of the relevant regulatory label and dossier owner, including:
- FDA (Orange Book) if US-listed
- EU (EMA/ national) if centrally or nationally authorized
- China (NMPA) if filed/approved
- national tender/stockist systems if not centrally approved
Which companies are ANCOBON suppliers in the US (Orange Book / FDA label)?
Answer: Not determinable.
US finished-dose (FDF) manufacturers
Listing suppliers require an FDA label match for ANCOBON (strength, dosage form, applicant/labeler) and an Orange Book entry, including patent listing or exclusivity records.
US API suppliers
API supplier identification depends on confirmed drug substance and a traceable manufacturing chain via:
- DMF holders and FDA confirmations
- inspection databases and contract manufacturing disclosures
- NDA/BLA owner and labeled manufacturing sites
Which companies supply ANCOBON in EU markets (EMA or national authorizations)?
Answer: Not determinable.
EU label holder vs. manufacturer
Supplier mapping in the EU typically separates:
- marketing authorization holder (MAH)
- manufacturer of record (batch release sites)
- contract manufacturers in the manufacturing chain
Which companies supply ANCOBON in China (NMPA approvals) and what are the distributors?
Answer: Not determinable.
China MAH and manufacturer-of-record
China supplier identification usually requires the NMPA approval number for the specific dosage form and strength and a linked MAH/manufacturer profile.
How strong is the ANCOBON patent estate that controls who can supply it?
Answer: Not determinable.
Patent barriers to generic or parallel supply
A defensible supplier landscape needs:
- granted formulation, method-of-use, and process patents
- Orange Book / national patent register mapping
- any litigation or settlement restricting supply
What generic or biosimilar entry risks exist for ANCOBON?
Answer: Not determinable.
Paragraph IV and approval pathway
Entry risk analysis requires:
- confirmed US approval pathway (ANDA vs 505(b)(2))
- any Paragraph IV challenges (if present)
- exclusivity end dates (NCE, 505(b)(2) exclusivity, pediatric, patent expiry)
What formulations and dosage forms determine supplier eligibility?
Answer: Not determinable.
Dose-form specificity
Supplier eligibility is often dose-form specific for:
- tablets vs capsules vs injections vs topical
- different strengths requiring different validated processes
What is the competitive supply landscape for ANCOBON by geography?
Answer: Not determinable.
Distributor networks vs manufacturer networks
Supplier “availability” can reflect:
- parallel import/distribution
- tender or hospital procurement channels
- licensed secondary distributors
Key Takeaways
- A supplier list for ANCOBON cannot be produced without a source-citable identification of the exact product (active ingredient, strength, dosage form) and its regulatory listing.
- Supplier mapping (API and finished-dose) depends on confirmed regulatory record ties (FDA/EU/China) and manufacturing-site disclosures.
FAQs
- Who manufactures ANCOBON’s active pharmaceutical ingredient (API)?
- Which company is the ANCOBON labeler of record in the US?
- Are there authorized generics or parallel imports of ANCOBON?
- Does ANCOBON have Orange Book patents or exclusivity impacting generic supply?
- Which contract manufacturing organizations (CMOs) produce ANCOBON dosage forms?
References
No sources cited.
